查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1372801

寡核苷酸合成市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按產品類型、按應用、最終用戶、地區和競爭細分

Oligonucleotide Synthesis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product Type, By Application, By End User, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 183 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

寡核苷酸合成市場到 2022 年價值 40.3 億美元，預計在預測期內將呈現強勁成長，預計到 2028 年年複合成長率 (CAGR) 為 13.30%。

該市場在生物技術和製藥行業中佔據著重要地位，代表著尖端研究和治療開發的交叉點。近年來，由於對應用於基因編輯、分子診斷和藥物發現等各個領域的客製化寡核苷酸的需求不斷成長，該行業經歷了顯著的擴張。這種激增可歸因於基因組學、個人化醫療和基於 RNA 的療法的快速發展，所有這些都嚴重依賴寡核苷酸的精確合成。隨著世界各地的組織在基因組學研究和分子診斷方面進行大量投資，寡核苷酸合成市場已成為關鍵的推動因素，使科學家能夠以無與倫比的精度獲得高品質、客製化的遺傳材料。

該市場的競爭格局由成熟的行業領導者和創新新創公司組成，形成了一個充滿活力的生態系統。自動化合成平台和新型化學修飾等技術進步正在提高寡核苷酸生產的效率和適應性，推動進一步擴張。此外，監管部門的批准和行業標準在確保合成寡核苷酸的品質和安全性、增強企業和研究人員的信心方面發揮關鍵作用。

市場概況
預測期 2024-2028
2022 年市場規模 40.3億美元
2028 年市場規模 85.2億美元
2023-2028 年年複合成長率 13.30%
成長最快的細分市場 療法
最大的市場 北美洲

隨著生物技術和製藥行業的不斷發展和多元化，寡核苷酸合成市場有望持續擴張。能夠提供具有成本效益的高品質寡核苷酸解決方案，同時保持在不斷發展的技術和監管要求的最前沿的公司無疑將在這個充滿活力的商業環境中蓬勃發展。該領域的戰略夥伴關係、研究合作和投資不僅正在重塑生命科學的格局，而且有望在醫療保健和生物技術領域取得突破性進展。因此，寡核苷酸合成市場是商業世界創新與進步的基石。

主要市場促進因素

基於RNA的治療

基於 RNA 的治療代表了製藥業的變革前沿，它們對寡核苷酸合成市場產生了重大影響。這些療法利用核糖核酸 (RNA) 分子（包括信使 RNA (mRNA)、小干擾 RNA (siRNA) 和反義寡核苷酸 (ASO)）的潛力來調節基因表現並治療多種疾病。寡核苷酸合成是基於 RNA 的療法的核心，因為它涉及針對疾病所涉及的特定基因序列或途徑客製化的合成 RNA 分子的精確設計和生產。

基因組研究的進展

基因組研究的進步促進了寡核苷酸合成市場的顯著成長。基因組研究的重點是解碼生物體的全部遺傳物質，在次世代定序 (NGS) 和 CRISPR-Cas9 基因編輯等技術的推動下，基因組研究發展迅速。這些創新導致對客製化寡核苷酸（短 DNA 或 RNA 序列）的需求大幅增加，這些寡核苷酸是遺傳分析、操作和定序的基本建構模組。

寡核苷酸合成市場為研究人員提供量身定做的遺傳材料，在這場基因組學革命中發揮關鍵作用。科學家需要這些寡核苷酸進行多種應用，包括全基因組定序、基因表現譜、表觀遺傳學研究和功能基因體學。隨著研究人員致力於破解疾病的遺傳基礎、識別生物標記並開發標靶療法，對高品質、精確寡核苷酸的需求不斷升級。

此外，單細胞基因組學的出現允許對異質組織內的單一細胞進行分析，這帶來了額外的複雜性和對專門寡核苷酸的需求。該領域的研究人員嚴重依賴獨特的寡核苷酸探針和引子來探索單細胞層面上基因表現和細胞多樣性的複雜性。

主要市場挑戰

效率和可擴展性

由於各種應用中對客製化寡核苷酸的需求不斷成長，效率和可擴展性是寡核苷酸合成市場的關鍵挑戰。效率對於確保合成過程不僅快速且精確且無錯誤至關重要。研究人員和製造商都需要可靠且一致的結果，任何低效率都可能導致延誤、成本增加和研究結果受損。另一方面，可擴展性圍繞著產業滿足寡核苷酸不斷成長的需求的能力，特別是隨著基因組學、基因療法和分子診斷的應用而不斷擴大。在維持品質標準的同時擴大生產是一項複雜的工作，通常需要在基礎設施、自動化和流程最佳化方面進行大量投資。

挑戰在於在效率和可擴展性之間取得平衡。雖然自動化和高通量技術提高了效率，但確保它們可擴展以滿足需求激增是一項持續的鬥爭。此外，長或高度修飾的寡核苷酸的合成可能特別具有挑戰性，因為它可能需要專門的設備和製程。此外，某些地區的監管限制需要嚴格的品質控制和文件記錄，這可能會影響效率和可擴展性工作。

成本限制

寡核苷酸合成市場的成本限制代表了影響研究和商業應用的多方面挑戰。寡核苷酸是廣泛的基因研究、診斷和治療開發工作的重要組成部分。然而，它們的合成，尤其是在處理長序列或化學修飾序列時，可能成本高昂。預算有限的研究人員經常面臨與採購客製化寡核苷酸相關的高額費用，這可能會限制他們的實驗範圍。此外，在基於 RNA 的療法中，生產大量高品質的合成 RNA 分子（例如用於疫苗或基因療法的 mRNA）可能涉及高昂的成本。平衡對具有成本效益的寡核苷酸的需求與精度和純度的要求是該行業面臨的持續挑戰。

寡核苷酸合成市場的公司也面臨成本相關的壓力。雖然自動化和合成技術的進步在一定程度上提高了效率並降低了成本，但市場內的競爭需要有競爭力的價格。對於那些希望在投資研發以保持該領域領先地位的同時保持利潤率的公司來說，這可能是一項挑戰。此外，化學修飾或特殊序列的結合會顯著增加生產成本，使成本效益方程式更加複雜。

主要市場趨勢

治療進展

治療進步代表了寡核苷酸合成市場的關鍵趨勢，開創了精準醫學和標靶治療的新時代。這一趨勢的特點是基於 RNA 的療法的開發和商業化，包括信使 RNA (mRNA) 疫苗和基因療法，它們嚴重依賴客製化寡核苷酸合成。 mRNA 疫苗，以 Pfizer-BioNTech 和 Moderna 的 COVID-19 疫苗為例，已經證明了合成 RNA 分子在不使用弱化或去活化病毒的情況下引發免疫反應的變革潛力。寡核苷酸合成是這些疫苗的核心，產生精確設計的編碼病毒抗原的 mRNA 序列。除了疫苗之外，寡核苷酸在基因治療中也發揮著至關重要的作用，它們被用來修飾、修復或取代導致遺傳性疾病的缺陷基因。

寡核苷酸合成市場是治療進步不可或缺的一部分，因為它提供了高精度和純度的必要原料—客製化設計的寡核苷酸。這使得研究人員和製藥公司能夠以前所未有的準確性和有效性開發基於 RNA 的療法。隨著基於 RNA 的治療研究擴展到解決各種疾病，包括癌症、罕見遺傳性疾病和自體免疫疾病，寡核苷酸合成市場有望呈指數級成長。它將繼續作為醫療保健領域創新和進步的基石，提供滿足全球醫療保健需求所需規模生產這些變革性療法的手段。因此，對於那些致力於為這個充滿活力且快速發展的領域做出貢獻的公司來說，保持寡核苷酸合成技術的前沿至關重要。

基因編輯和 CRISPR-Cas9

基因編輯，特別是透過革命性的 CRISPR-Cas9 技術，已成為寡核苷酸合成市場的主要驅動力。 CRISPR-Cas9 是一種多功能基因組編輯工具，依賴寡核苷酸的精確設計和合成來靶向和修改生物體基因組內的特定 DNA 序列。寡核苷酸稱為引導 RNA (gRNA)，經過合成工程改造以補充標靶 DNA，引導 Cas9 酶到達所需的基因組位置進行編輯。這項技術開啟了基因研究的新可能性，使研究人員能夠以前所未有的精度操縱基因，應用於從基礎研究到治療介入的各種應用。

寡核苷酸合成市場透過提供客製化設計的 gRNA 和用於基因編輯的供體 DNA 模板，在支援 CRISPR-Cas9 應用方面發揮關鍵作用。研究人員和生物技術公司需要這些寡核苷酸來促進精確修飾，例如基因敲除、基因插入或鹼基對替換。快速生產適合特定基因編輯實驗的高品質寡核苷酸的能力對於推進基於 CRISPR 的基因組工程領域至關重要。

隨著基因編輯在農業、醫學和生物技術等領域的不斷擴展，寡核苷酸合成市場有望大幅成長。能夠根據CRISPR-Cas9 應用的獨特要求提供經濟高效、可靠和可客製化的寡核苷酸解決方案的公司將仍然是這個充滿活力和變革的領域的重要參與者，推動遺傳學和生物技術的創新和進步。

細分市場洞察

應用洞察

治療領域在寡核苷酸合成市場中佔據主導地位，預計在未來幾年將繼續擴大。寡核苷酸合成市場的治療領域已經確立了主導地位，並且由於幾個關鍵因素而有望持續成長。首先，基於 RNA 的療法，包括信使 RNA (mRNA) 疫苗和基因療法的出現，為製藥業帶來了巨大的轉變。寡核苷酸合成是這些變革性治療的核心，因為它能夠精確、客製化地生產對治療效果至關重要的合成 RNA 分子。 mRNA 疫苗的成功（其在 COVID-19 大流行期間的快速發展和全球部署就是例證）強調了寡核苷酸合成在解決緊迫的醫療保健挑戰方面的潛力。

其次，個人化醫療的趨勢已獲得相當大的發展動能。根據個別患者的基因譜客製化治療方法需要開發高度特異性和標靶的療法，其中許多涉及寡核苷酸。客製化寡核苷酸對於基因編輯、RNA 干擾和其他精準醫學方法至關重要。隨著這一趨勢持續影響製藥領域，寡核苷酸合成的需求必將飆升。

此外，寡核苷酸合成市場在治療領域的應用範圍不斷擴大，包括遺傳性疾病、癌症、傳染病和罕見疾病的治療。這些應用需要生產修飾的寡核苷酸，以增強穩定性、特異性和治療效果，從而推動治療領域的進一步成長。

最後，監管部門的批准和基於寡核苷酸的治療領域不斷增加的研究合作為市場注入了信心。監管機構正在為基於寡核苷酸的藥物的開發和批准提供更清晰的途徑，進一步推動治療領域的擴張。

區域洞察

北美地區已成為 2022 年寡核苷酸合成市場的領導者。由於幾個令人信服的原因，北美已成為 2022 年寡核苷酸合成市場的領導者。首先，該地區擁有發達且高度創新的製藥和生物技術產業。尤其是美國，擁有眾多領先的生物技術公司和研究機構，這些公司和研究機構推動了從基因組學研究到治療開發等各種應用中對客製化寡核苷酸的需求。這些行業領導者的強大存在創造了一個繁榮的生態系統，促進創新、研究合作和市場成長。其次，北美受惠於醫療保健和生命科學研究的大量投資。政府資金、私人投資和風險資本紛紛湧入該地區，以支持尖端基因組研究、基因療法和基於 RNA 的療法。隨著研究人員為其計畫尋找可靠且專業的合作夥伴，這些財務支持刺激了對寡核苷酸合成服務的需求。此外，北美的監管環境有利於基於寡核苷酸的治療。美國食品藥物管理局 (FDA) 等監管機構已經制定了批准寡核苷酸藥物和療法的明確途徑和指南，增強了市場信心並促進新產品的商業化。此外，該地區對精準醫療和個人化醫療保健的高度重視推動了寡核苷酸合成市場的成長。利用客製化設計的寡核苷酸來針對特定遺傳標記或突變的客製化療法符合北美的醫療保健優先事項，有助於市場擴張。最後，北美完善的基礎設施和物流網路確保了高效的供應鏈和寡核苷酸的及時交付，進一步增強了其競爭優勢。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球寡核苷酸合成市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型（合成寡核苷酸產品、試劑、設備和服務）
    • 按應用（研究、治療和診斷）
    • 按最終用戶（學術研究機構、製藥和生物技術公司以及醫院和診斷實驗室）
    • 按地區
    • 按公司分類 (2022)
  • 市場地圖

第 6 章：北美寡核苷酸合成市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲寡核苷酸合成市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太寡核苷酸合成市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲寡核苷酸合成市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章 ：中東和非洲寡核苷酸合成市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非寡核苷酸合成
    • 沙烏地阿拉伯寡核苷酸合成
    • 阿拉伯聯合大公國寡核苷酸合成

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 近期發展
  • 併購

第 13 章：全球寡核苷酸合成市場：SWOT 分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代治療類型的威脅

第15章：競爭格局

  • 商業概覽
  • 服務內容
  • 最近的發展
  • 主要人員
  • SWOT分析
    • Thermo Fisher Scientific Inc
    • Agilent Technologies, Inc.
    • Merck KGaA
    • BIO-Synthesis Inc
    • Eurofins Scientific SE
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Biogen Inc.
    • Ionis Pharmaceuticals, Inc.
    • Sarepta Therapeutics, Inc.

第 16 章：策略建議

第 17 章：關於我們與免責聲明

簡介目錄
Product Code: 16306

The Oligonucleotide Synthesis Market, valued at USD 4.03 Billion in 2022, is expected to exhibit robust growth in the forecast period, with an anticipated Compound Annual Growth Rate (CAGR) of 13.30% through 2028.

This market occupies a prominent position in the biotechnology and pharmaceutical industries, representing the intersection of cutting-edge research and therapeutic development. In recent years, this sector has experienced remarkable expansion, driven by the growing demand for custom-designed oligonucleotides applied in various fields, including gene editing, molecular diagnostics, and drug discovery. This surge can be attributed to the rapid growth of genomics, personalized medicine, and RNA-based therapeutics, all of which heavily rely on the precise synthesis of oligonucleotides. As organizations worldwide make significant investments in genomics research and molecular diagnostics, the oligonucleotide synthesis market has become a critical enabler, granting scientists access to high-quality, tailor-made genetic material with unparalleled precision.

The competitive landscape in this market comprises a mix of well-established industry leaders and innovative startups, fostering a dynamic ecosystem. Technological advancements, such as automated synthesis platforms and novel chemical modifications, are enhancing the efficiency and adaptability of oligonucleotide production, fueling further expansion. Furthermore, regulatory approvals and industry standards play a pivotal role in ensuring the quality and safety of synthesized oligonucleotides, instilling confidence in businesses and researchers alike.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 4.03 Billion
Market Size 2028USD 8.52 Billion
CAGR 2023-202813.30%
Fastest Growing SegmentTherapeutics
Largest MarketNorth America

As the biotechnology and pharmaceutical sectors continue to grow and diversify, the oligonucleotide synthesis market is positioned for sustained expansion. Companies that can provide cost-effective, high-quality oligonucleotide solutions while remaining at the forefront of evolving technologies and regulatory requirements will undoubtedly thrive in this dynamic business environment. The strategic partnerships, research collaborations, and investments in this field are not only reshaping the landscape of life sciences but also holding the promise of groundbreaking advancements in healthcare and biotechnology. Consequently, the oligonucleotide synthesis market is a cornerstone of innovation and progress in the business world.

Key Market Drivers

RNA-Based Therapeutics

RNA-Based Therapeutics represent a transformative frontier in the pharmaceutical industry, and they have a significant impact on the oligonucleotide synthesis market. These therapeutics harness the potential of ribonucleic acid (RNA) molecules, including messenger RNA (mRNA), small interfering RNA (siRNA), and antisense oligonucleotides (ASOs), to modulate gene expression and treat a wide array of diseases. Oligonucleotide synthesis is at the heart of RNA-based therapeutics, as it involves the precise design and production of synthetic RNA molecules tailored to target specific genetic sequences or pathways involved in diseases.

One of the most notable breakthroughs in this field has been the development of mRNA vaccines, exemplified by the COVID-19 vaccines produced by Pfizer-BioNTech and Moderna. These vaccines employ synthetic mRNA to instruct cells to produce viral spike proteins, triggering an immune response without using weakened or inactivated viruses. The rapid success of mRNA vaccines has demonstrated the power and versatility of RNA-based therapeutics, creating a surge in demand for custom oligonucleotides used in their formulation. Oligonucleotide synthesis companies are now focusing on optimizing and scaling up production processes to meet this heightened demand.

Moreover, RNA-based therapeutics are gaining traction in treating genetic disorders, cancers, and rare diseases. ASOs and siRNAs, for instance, can selectively inhibit the expression of disease-causing genes, offering potential cures or symptom management. The design and synthesis of these oligonucleotides must be highly precise to ensure therapeutic efficacy and minimize off-target effects.

Advancements in Genomic Research

Advancements in Genomic Research have catalyzed a remarkable growth trajectory for the oligonucleotide synthesis market. Genomic research, which focuses on decoding the entirety of an organism's genetic material, has evolved rapidly, powered by technologies like Next-Generation Sequencing (NGS) and CRISPR-Cas9 gene editing. These innovations have led to a substantial increase in the demand for custom-designed oligonucleotides - short DNA or RNA sequences - that serve as the fundamental building blocks for genetic analysis, manipulation, and sequencing.

The oligonucleotide synthesis market plays a pivotal role in this genomics revolution by supplying researchers with tailor-made genetic material. Scientists require these oligonucleotides for a myriad of applications, including whole-genome sequencing, gene expression profiling, epigenetic studies, and functional genomics. As researchers aim to decipher the genetic basis of diseases, identify biomarkers, and develop targeted therapies, the need for high-quality, precise oligonucleotides continues to escalate.

Moreover, the emergence of single-cell genomics, which allows for the analysis of individual cells within heterogeneous tissues, has introduced additional complexity and demand for specialized oligonucleotides. Researchers in this field rely heavily on unique oligonucleotide probes and primers to explore the intricacies of gene expression and cellular diversity at the single-cell level.

Key Market Challenges

Efficiency and Scalability

Efficiency and scalability are critical challenges in the oligonucleotide synthesis market, driven by the escalating demand for custom oligonucleotides in various applications. Efficiency is crucial in ensuring that the synthesis processes are not only fast but also precise and error-free. Researchers and manufacturers alike require reliable and consistent results, and any inefficiencies can lead to delays, increased costs, and compromised research outcomes. Scalability, on the other hand, revolves around the industry's ability to meet the growing demand for oligonucleotides, especially with the expanding applications of genomics, gene therapy, and molecular diagnostics. Scaling up production while maintaining quality standards is a complex endeavor, often requiring significant investments in infrastructure, automation, and process optimization.

The challenge lies in striking a balance between efficiency and scalability. While automation and high-throughput technologies have improved efficiency, ensuring they are scalable to meet the surge in demand is a constant struggle. Additionally, the synthesis of long or highly modified oligonucleotides can be particularly challenging, as it may require specialized equipment and processes. Furthermore, regulatory constraints in some regions necessitate rigorous quality control and documentation, which can impact efficiency and scalability efforts.

Cost Constraints

Cost constraints in the oligonucleotide synthesis market represent a multifaceted challenge that impacts both research and commercial applications. Oligonucleotides are essential components in a wide range of genetic research, diagnostics, and therapeutic development endeavors. However, their synthesis, especially when dealing with long or chemically modified sequences, can be cost-prohibitive. Researchers operating on limited budgets often grapple with the high expenses associated with procuring custom oligonucleotides, potentially limiting the scope of their experiments. Moreover, in the context of RNA-based therapeutics, the production of large quantities of high-quality synthetic RNA molecules, such as mRNA for vaccines or gene therapies, can involve significant costs. Balancing the need for cost-effective oligonucleotides with the requirement for precision and purity is a constant challenge for the industry.

Companies in the oligonucleotide synthesis market also face cost-related pressures. While advancements in automation and synthesis technologies have improved efficiency and reduced costs to some extent, competition within the market necessitates competitive pricing. This can be challenging for companies looking to maintain profit margins while investing in research and development to stay at the forefront of the field. Additionally, the incorporation of chemical modifications or specialized sequences can significantly increase production costs, further complicating the cost-effectiveness equation.

Key Market Trends

Therapeutic Advancements

Therapeutic advancements represent a pivotal trend in the oligonucleotide synthesis market, ushering in a new era of precision medicine and targeted therapies. This trend is characterized by the development and commercialization of RNA-based therapeutics, including messenger RNA (mRNA) vaccines and gene therapies, which rely heavily on custom oligonucleotide synthesis. mRNA vaccines, exemplified by the COVID-19 vaccines from Pfizer-BioNTech and Moderna, have demonstrated the transformative potential of synthetic RNA molecules in eliciting immune responses without using weakened or inactivated viruses. Oligonucleotide synthesis is at the core of these vaccines, producing precisely designed mRNA sequences encoding viral antigens. Beyond vaccines, oligonucleotides play a crucial role in gene therapies, where they are used to modify, repair, or replace defective genes responsible for genetic disorders.

The oligonucleotide synthesis market is integral to therapeutic advancements as it provides the essential raw materials - custom-designed oligonucleotides - with high precision and purity. This allows researchers and pharmaceutical companies to develop RNA-based therapeutics with unprecedented accuracy and efficacy. As research in RNA-based treatments expands to address various diseases, including cancer, rare genetic disorders, and autoimmune conditions, the oligonucleotide synthesis market is poised to grow exponentially. It will continue to serve as a cornerstone of innovation and progress in healthcare, offering the means to manufacture these transformative therapeutics on a scale required to meet global healthcare needs. Consequently, staying at the forefront of oligonucleotide synthesis technologies is critical for companies aiming to contribute to this dynamic and rapidly evolving field.

Gene Editing and CRISPR-Cas9

Gene editing, particularly through the revolutionary CRISPR-Cas9 technology, has emerged as a major driving force in the oligonucleotide synthesis market. CRISPR-Cas9, a versatile genome-editing tool, relies on the precise design and synthesis of oligonucleotides to target and modify specific DNA sequences within an organism's genome. Oligonucleotides, known as guide RNAs (gRNAs), are synthetically engineered to complement the target DNA, guiding the Cas9 enzyme to the desired genomic location for editing. This technology has unlocked new possibilities in genetic research, enabling researchers to manipulate genes with unprecedented precision for applications ranging from fundamental research to therapeutic interventions.

The oligonucleotide synthesis market plays a pivotal role in supporting CRISPR-Cas9 applications by providing custom-designed gRNAs and donor DNA templates for gene editing. Researchers and biotechnology companies require these oligonucleotides to facilitate precise modifications, such as gene knockouts, gene insertions, or base pair substitutions. The ability to rapidly produce high-quality oligonucleotides tailored to specific gene-editing experiments is crucial for advancing the field of CRISPR-based genome engineering.

As gene editing continues to expand in areas like agriculture, medicine, and biotechnology, the oligonucleotide synthesis market is poised for substantial growth. Companies that can offer cost-effective, reliable, and customizable oligonucleotide solutions tailored to the unique requirements of CRISPR-Cas9 applications will remain essential players in this dynamic and transformative field, driving innovation and progress in genetics and biotechnology.

Segmental Insights

Application Insights

The Therapeutic Segment dominates the Oligonucleotide Synthesis market and is predicted to continue expanding over the coming years. The therapeutic segment of the oligonucleotide synthesis market has established dominance and is poised for sustained growth due to several key factors. Firstly, the advent of RNA-based therapeutics, including messenger RNA (mRNA) vaccines and gene therapies, has created a seismic shift in the pharmaceutical industry. Oligonucleotide synthesis is at the core of these transformative treatments, as it enables the precise and customized production of synthetic RNA molecules critical for therapeutic efficacy. The success of mRNA vaccines, exemplified by their rapid development and global deployment during the COVID-19 pandemic, has underscored the potential of oligonucleotide synthesis in addressing pressing healthcare challenges.

Secondly, the trend toward personalized medicine has gained considerable momentum. Tailoring treatments to individual patients' genetic profiles requires the development of highly specific and targeted therapies, many of which involve oligonucleotides. Customized oligos are essential for gene editing, RNA interference, and other precision medicine approaches. As this trend continues to shape the pharmaceutical landscape, the demand for oligonucleotide synthesis is set to soar.

Furthermore, the oligonucleotide synthesis market is witnessing an expanding range of applications within therapeutics, including the treatment of genetic disorders, cancer, infectious diseases, and rare conditions. These applications necessitate the production of modified oligonucleotides that enhance stability, specificity, and therapeutic effectiveness, driving further growth in the therapeutic segment.

Lastly, regulatory approvals and increasing research collaborations in the oligonucleotide-based therapeutic space have instilled confidence in the market. Regulatory agencies are providing clearer pathways for the development and approval of oligonucleotide-based drugs, further propelling the therapeutic segment's expansion.

Regional Insights

The North America region has established itself as the leader in the Oligonucleotide Synthesis Market in 2022. North America has emerged as the frontrunner in the oligonucleotide synthesis market in 2022 for several compelling reasons. Firstly, the region boasts a well-developed and highly innovative pharmaceutical and biotechnology industry. The United States, in particular, is home to numerous leading biotech companies and research institutions that drive the demand for custom oligonucleotides in various applications, from genomics research to therapeutic development. The robust presence of these industry leaders has created a thriving ecosystem that fosters innovation, research collaborations, and market growth. Secondly, North America benefits from a substantial investment in healthcare and life sciences research. Government funding, private investments, and venture capital have poured into the region to support cutting-edge genomic studies, gene therapies, and RNA-based therapeutics. These financial backing fuels the demand for oligonucleotide synthesis services, as researchers seek reliable and specialized partners for their projects. Additionally, the regulatory environment in North America is conducive to oligonucleotide-based therapeutics. Regulatory agencies like the U.S. Food and Drug Administration (FDA) have developed clear pathways and guidelines for the approval of oligonucleotide drugs and therapies, instilling confidence in the market and facilitating the commercialization of novel products. Moreover, the region's strong emphasis on precision medicine and personalized healthcare has propelled the growth of the oligonucleotide synthesis market. Tailored therapies that utilize custom-designed oligonucleotides to target specific genetic markers or mutations align with North America's healthcare priorities, contributing to market expansion. Lastly, North America's well-established infrastructure and logistics networks ensure efficient supply chains and timely delivery of oligonucleotides, further enhancing its competitive advantage.

Key Market Players

  • Thermo Fisher Scientific Inc
  • Agilent Technologies, Inc.
  • Merck KGaA
  • BIO-Synthesis Inc
  • Eurofins Scientific SE
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Biogen Inc.
  • Ionis Pharmaceuticals, Inc.
  • Sarepta Therapeutics, Inc.

Report Scope:

In this report, the Oligonucleotide Synthesis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oligonucleotide Synthesis Market, Product Type:

  • Synthesized Oligonucleotide Products
  • Reagents
  • Equipment
  • Services

Oligonucleotide Synthesis Market, Application:

  • Research
  • Therapeutics
  • Diagnostics

Oligonucleotide Synthesis Market, End User:

  • Academic Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Hospital & Diagnostic Laboratories

Oligonucleotide Synthesis Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • United Kingdom
  • Italy
  • France
  • Spain
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Oligonucleotide Synthesis Market.

Available Customizations:

  • Oligonucleotide Synthesis Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oligonucleotide Synthesis Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Synthesized Oligonucleotide Products, Reagents, Equipment, and Services)
    • 5.2.2. By Application (Research, Therapeutics, and Diagnostics)
    • 5.2.3. By End User (Academic Research Institutes, Pharmaceutical and Biotechnology Companies, and Hospital and Diagnostic Laboratories)
    • 5.2.4. By Region
    • 5.2.5. By Company (2022)
  • 5.3. Market Map

6. North America Oligonucleotide Synthesis Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Oligonucleotide Synthesis Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Oligonucleotide Synthesis Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Oligonucleotide Synthesis Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End User

7. Europe Oligonucleotide Synthesis Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Oligonucleotide Synthesis Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. United Kingdom Oligonucleotide Synthesis Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. Italy Oligonucleotide Synthesis Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User
    • 7.3.4. France Oligonucleotide Synthesis Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Oligonucleotide Synthesis Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End User

8. Asia-Pacific Oligonucleotide Synthesis Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Oligonucleotide Synthesis Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. India Oligonucleotide Synthesis Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Oligonucleotide Synthesis Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Oligonucleotide Synthesis Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Oligonucleotide Synthesis Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End User

9. South America Oligonucleotide Synthesis Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Oligonucleotide Synthesis Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Oligonucleotide Synthesis Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Oligonucleotide Synthesis Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User

10. Middle East and Africa Oligonucleotide Synthesis Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Oligonucleotide Synthesis Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Oligonucleotide Synthesis Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Oligonucleotide Synthesis Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions

13. Global Oligonucleotide Synthesis Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Treatment Types

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Service Offerings
  • 15.3. Recent Developments
  • 15.4. Key Personnel
  • 15.5. SWOT Analysis
    • 15.5.1. Thermo Fisher Scientific Inc
    • 15.5.2. Agilent Technologies, Inc.
    • 15.5.3. Merck KGaA
    • 15.5.4. BIO-Synthesis Inc
    • 15.5.5. Eurofins Scientific SE
    • 15.5.6. Danaher Corporation
    • 15.5.7. Agilent Technologies, Inc.
    • 15.5.8. Biogen Inc.
    • 15.5.9. Ionis Pharmaceuticals, Inc.
    • 15.5.10. Sarepta Therapeutics, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer